Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Phillip Pymm, Amy Adair, Li‐Jin Chan, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 19
Open Access | Times Cited: 143

Showing 26-50 of 143 citing articles:

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
Adam K. Wheatley, Phillip Pymm, Robyn Esterbauer, et al.
Cell Reports (2021) Vol. 37, Iss. 2, pp. 109822-109822
Open Access | Times Cited: 46
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Lennox Chitsike, Penelope J. Duerksen-Hughes
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 42
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
I. A. FAVORSKAYA, Dmitry V. Shcheblyakov, I. B. Esmagambetov, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 33
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Huan Ma, Xinghai Zhang, Peiyi Zheng, et al.
Cell Research (2022) Vol. 32, Iss. 9, pp. 831-842
Open Access | Times Cited: 29
The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
Dhaneshree Bestinee Naidoo, Anil A. Chuturgoon
Molecular Diagnosis & Therapy (2023) Vol. 27, Iss. 2, pp. 193-226
Open Access | Times Cited: 20
Expanding and improving nanobody repertoires using a yeast display method: Targeting SARS-CoV-2
Frederick R. Cross, Peter C. Fridy, Natalia E. Ketaren, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 3, pp. 102954-102954
Open Access | Times Cited: 17
Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy
Yufei Xiang, Jialu Xu, Briana L. McGovern, et al.
Cell (2024)
Closed Access | Times Cited: 7
Prospects of Neutralizing Nanobodies Against SARS-CoV-2
Fangfang Chen, Zhihong Liu, Fan Jiang
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 37
Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron
José M. Casasnovas, Yago Margolles, María A. Noriega, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 28
Superimmunity by pan-sarbecovirus nanobodies
Yufei Xiang, Wei Huang, Hejun Liu, et al.
Cell Reports (2022) Vol. 39, Iss. 13, pp. 111004-111004
Open Access | Times Cited: 28
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
Jules B. Weinstein, Timothy A. Bates, Hans C. Leier, et al.
iScience (2022) Vol. 25, Iss. 3, pp. 103960-103960
Open Access | Times Cited: 27
Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
Martín A. Rossotti, Henk van Faassen, Anh Tran, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 27
Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes
Halina Mikolajek, Miriam Weckener, Z. Faidon Brotzakis, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 31
Open Access | Times Cited: 26
Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review
Hamid Aria, Fatemeh Mahmoodi, Hooria Seyedhosseini Ghaheh, et al.
Analytical Biochemistry (2022) Vol. 640, pp. 114546-114546
Open Access | Times Cited: 25
A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein
Vito Thijssen, Daniel L. Hurdiss, Oliver J. Debski-Antoniak, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 26
Open Access | Times Cited: 15
Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD
Xiaochun Liu, Yanqing Wang, Li-shan Sun, et al.
Antiviral Research (2024) Vol. 226, pp. 105898-105898
Closed Access | Times Cited: 6
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update
Md. Easin Mia, Mithu Howlader, Farzana Akter, et al.
Clinical Pathology (2024) Vol. 17
Open Access | Times Cited: 6
Nanobody engineering for SARS-CoV-2 neutralization and detection
Liina Hannula, Suvi Kuivanen, Jonathan Lasham, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 5
Statewide Interventions and Coronavirus Disease 2019 Mortality in the United States: An Observational Study
Nadir Yehya, Atheendar Venkataramani, Michael O. Harhay
Clinical Infectious Diseases (2020) Vol. 73, Iss. 7, pp. e1863-e1869
Open Access | Times Cited: 37
Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity
Brandon Havranek, Kui K. Chan, Austin Wu, et al.
Journal of Chemical Information and Modeling (2021) Vol. 61, Iss. 9, pp. 4656-4669
Closed Access | Times Cited: 31
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
Georgia Deliyannis, Nicholas A. Gherardin, Chinn Yi Wong, et al.
EBioMedicine (2023) Vol. 92, pp. 104574-104574
Open Access | Times Cited: 13
Molecular mechanisms and cellular functions of liquid-liquid phase separation during antiviral immune responses
Shuai Yang, Weishan Shen, Jiajia Hu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters
Metin Aksu, Priya Kumar, Thomas Güttler, et al.
Antiviral Research (2023) Vol. 221, pp. 105778-105778
Open Access | Times Cited: 13
Multi-omics for COVID-19: driving development of therapeutics and vaccines
Mengyu Guo, Muya Xiong, Jinying Peng, et al.
National Science Review (2023) Vol. 10, Iss. 9
Open Access | Times Cited: 12
Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus
Xuemei Feng, Hu Wang
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 7, pp. 925-942
Open Access | Times Cited: 11

Scroll to top